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A B S T R A C T 
It has been speculated that extracorporeal blood 
purification therapies might improve the clinical 
outcome for patients with severe sepsis, with or 
without acute kidney injury, since the removal of 
inflammatory mediators and/or bacterial toxins 
from circulation could modulate the inflammatory 
responses that result in organ damage. Despite initial 
enthusiasm based on promising preliminary results, 
subsequent investigations did not show sustainable 
survival benefit. We review the principles and 
development of blood purification techniques for 
sepsis and septic acute kidney injury. 
Extracorporeal blood purification for sepsis
Introduction
The concepts underlying the pathogenesis of 
septic acute kidney injury (AKI) are complex. 
It is characterised by renal macro- and micro-
circulatory disturbance, surge of inflammatory 
markers, and de-regulation of oxidative stress, 
followed by a bioenergetic adaptive response and 
controlled cell cycle arrest aimed at preventing cell 
death.1 Continuous renal replacement therapy is 
commonly performed in the critical care setting for 
patients with septic AKI. The use of low- or normal-
volume continuous venovenous haemodialysis or 
haemofiltration, however, has failed to demonstrate 
any improvement of patient outcome in severe 
sepsis.2,3 Extracorporeal blood purification therapies 
have been proposed to improve the outcome 
for patients with severe sepsis with and without 
AKI. The underlying principle is the removal of 
excessive inflammatory mediators and/or bacterial 
toxins from the blood compartment in order to 
modulate the inflammatory response. This involves 
various techniques including haemoperfusion/
haemoadsorption, high-adsorption haemofiltration, 
high-volume haemofiltration (HVHF), high cut-off 
(HCO) membrane haemofiltration/haemodialysis, 
plasma exchange, and coupled plasma filtration 
adsorption (CPFA) [Table 1]. These techniques 
are gaining popularity in Europe and Japan. This 
overview discusses the concept and latest advances 
in blood purification for sepsis and septic AKI. 
Therapeutic concept of 
extracorporeal blood purification
During sepsis, triacylated peptides, diacylated 
peptides, or lipopolysaccharides (LPS) are released 
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by pathogens, and are recognised by the Toll-
like receptors located on the surface of antigen-
presenting cells.4,5 Toll-like receptors also recognise 
locally produced damage-associated molecular 
patterns (DAMPs) from ischaemic renal tissue 
and circulating DAMPs released from extensive 
extrarenal tissue damage in sepsis.6 This triggers 
the activation of leukocytes, endothelial cells, and 
epithelial cells that release more inflammatory 
mediators such as tumour necrosis factor–alpha 
(TNF-α), interleukin-1 (IL-1), IL-6, IL-8 and IL-10, 
causing cellular and tissue damage.7,8 This is called a 
‘cytokine storm’, and can also occur in non-infectious 
conditions such as severe trauma, extensive burns, 
acute necrotising pancreatitis, and post–cardiac 
arrest. A cytokine storm per se, in the absence 
of life-threatening triggering factors, can induce 
haemodynamic instability and multi-organ failure 
as illustrated by Suntharalingam et al.9 Moreover, 
immunoparalysis might occur after a cytokine storm 
and contribute to severe secondary nosocomial 
infections.10 As demonstrated in a postmortem by 
Boomer et al,11 patients who die of severe sepsis 
have biochemical and immunohistochemical 
findings consistent with immunosuppression. This 
gives rise to the concept of immunomodulation in 
sepsis. Low-dose steroid administration has been 
shown to improve septic shock reversal but is not 
associated with any survival benefits and is currently 
out of favour.12,13 The clinical benefit of intravenous 
immunoglobulins and anti–TNF-α in the treatment 
of severe sepsis is controversial and inconclusive.14,15 
Blood purification may offer non-specific clearance 
of inflammatory mediators and/or microbial toxins 
and thus help to restore immune homeostasis. Five 
theories have been proposed to explain the potential 
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體外血液淨化療法治療膿毒症
沈海平、殷榮華、陳德茂
體外血液淨化療法能去除血液中過多炎症介質和/或細菌毒素以達至調
節炎症反應效果，因此被推測在有或沒有急性腎損傷情況下能改善嚴
重膿毒症的治療效果。初期研究的結果令人鼓舞，可惜及後的研究未
能證實可延長病人的存活。本文回顧體外血液淨化療法對於膿毒症及
膿毒性急性腎損傷的原理和發展。
benefit of blood purification in sepsis. First, Ronco 
et al16 proposed the “cytokine peak concentration 
hypothesis” and suggested that eliminating the peaks 
in cytokine blood concentration during the early 
phase of sepsis could stop the inflammatory cascade, 
limit organ damage, and consequently decrease the 
incidence of multi-organ failure syndrome. Second, 
Honoré and Matson17 proposed the “threshold 
immunomodulation hypothesis” that indicated 
cytokines will equilibrate between the blood and 
tissue compartments. This provided an explanation 
for the clinical benefit of blood purification 
techniques even without any significant changes in 
cytokine level within the blood compartment. Third, 
Di Carlo and Alexander18 proposed the “mediator 
delivery hypothesis” and suggested that high-volume 
fluid replacement during haemofiltration might 
promote lymphatic flow and displace inflammatory 
mediators to the blood compartment, making them 
available for removal. Fourth, Peng et al19 suggested 
that blood purification therapies could act directly at 
the cellular level to restore immune function. Finally, 
Rimmelé and Kellum20 proposed the “cytokinetic 
model” which indicated that blood purification 
techniques remove cytokines from the blood 
compartment and widen the cytokine/chemokine 
concentration gradient between blood and infected 
tissue. This improves leukocyte trafficking towards 
the infective foci, and thus promotes bacterial killing. 
Haemoperfusion/haemoadsorption
This technique binds toxins and other mediators in 
the extracorporeal circuit and removes them from 
the blood compartment.20 The sorbents, which 
consist of microfibres or resin-covered beads, are 
normally contained in cartridges that are placed 
in series within the extracorporeal circuit. They 
have a selective or non-selective binding capacity 
for cytokines, chemokines, super-antigens, or 
endotoxins by means of hydrophobic interaction, 
van der Waals forces, or ionic interactions.20 Initial 
clinical applications were complicated by severe 
thrombocytopenia and leukopenia but these were 
TABLE 1.  Comparison between major blood purification techniques
Therapy Mode of action Comments
Polymyxin B–immobilised fibre column 
(Toraymyxin; Toray Industries, Tokyo, Japan) 
Endotoxin haemoadsorption •	 Potential	mortality	benefit	based	on	RCTs
•	 Well-studied	treatment	modality
•	 Not	available	locally
MATISSE-Fresenius system (Fresenius SE, 
Bad Homburg, Germany)
Endotoxin haemoadsorption •	 Multicentre	RCT	showed	no	significant	clinical	
benefit
Alteco LPS Adsorber (Alteco Medical AB, 
Lund, Sweden) 
Endotoxin haemoadsorption •	 Limited	clinical	experience
•	 Ex-vivo	study	showed	unacceptable	LPS	clearance
Cytokines haemoadsorptive device Cytokine haemoadsorption •	 Good	cytokine	clearance
•	 Limited	clinical	experience
oXiris haemofilter (Gambro Hospal, Stockholm, 
Sweden)
Endotoxin and cytokine haemoadsorption 
plus renal support
•	 Simple	and	familiar	technique
•	 Limited	clinical	experience
PMMA haemofilter Cytokine haemoadsorption plus renal 
support
•	 Simple	and	familiar	technique
•	 No	RCT	available
•	 Low	cost
HVHF Haemofiltration •	 Well-studied	treatment	modality	
•	 No	survival	or	haemodynamic	benefit
High cut-off haemofiltration/haemodialysis Cytokine removal by haemofiltration/
haemodialysis
•	 Simple	and	familiar	technique
•	 One	unpublished	RCT	showed	no	mortality	or	other	
clinical benefit
Plasmapheresis Cytokine removal by haemofiltration •	 Conflicting	results	from	RCTs
•	 Loss	of	vital	component	during	prolonged	treatment
CPFA Cytokine removal by haemofiltration and 
haemoadsorption
•	 One	RCT	showed	no	mortality	benefit
•	 More	complicated	setup	when	compared	with	other	
blood purification techniques
Abbreviations: CPFA = coupled plasma filtration adsorption; HVHF = high-volume haemofiltration; LPS = lipopolysaccharides; PMMA = 
polymethylmethacrylate; RCT = randomised controlled trial
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subsequently managed using a biocompatible 
coating. 
Polymyxin B–immobilised fibre column
Polymyxin B (PMX)–immobilised fibre column 
haemoperfusion (Toraymyxin, Toray Industries, 
Tokyo, Japan) is the most commonly used approach, 
and has been used for the treatment of septic shock 
since 1994 in Japan and since 2002 in Europe. It 
has gained popularity worldwide in recent years, 
especially after the landmark EUPHAS (Early Use 
of Polymyxin B Hemoperfusion in Abdominal 
Sepsis) study.21 The PMX is a group of cyclic cationic 
polypeptide antibiotics derived from Bacillus 
polymyxa. Endotoxins are heat and pH stable, and 
thus can be difficult to remove from protein-rich 
solutions such as blood. The PMX is capable of 
binding and neutralising endotoxins. Nephrotoxicity 
and neurotoxicity, however, are very common and 
thus limit their clinical use.22 To overcome this 
problem, PMX is immobilised onto polystyrene 
fibres that effectively remove endotoxin without 
leaching. The blood is perfused at a rate of 80 to 100 
mL/min through a PMX-immobilised fibre column. 
Anticoagulation is achieved using unfractionated 
heparin, low-molecular-weight heparin, or the 
protease inhibitor nafamostat mesylate. Treatment 
usually lasts for 2 to 27 hours once or in some 
patients up to 4 times, depending on the clinical 
response. Three meta-analyses (approximately 1000 
patients) were published before 2015: Studies by 
Mitaka and Tomita23 (17 studies, 975 patients) and 
Cruz et al24 (28 studies, 1425 patients) included 
both randomised controlled trials (RCTs) and 
observational studies. When reported, Gram-
negative infections were identified in approximately 
70% of patients (range, 37.9%-100% in individual 
studies). In general, PMX treatment led to significant 
haemodynamic improvement with a reduction 
in the use of inotropic agents/vasopressors in 
patients with sepsis. Moreover, it was associated 
with a decreased endotoxin level, modulation of 
inflammatory markers, and improvement of the 
PaO2/FiO2 ratio (ratio of the partial pressure of 
oxygen in arterial blood to the inspired oxygen 
fraction) in most included studies.23,24 Treatment 
by PMX significantly reduced 28-day mortality 
compared with conventional therapy. The meta-
analysis by Zhou et al25 (8 studies, 370 patients) 
included RCTs only and focused on mortality, 
and showed significant survival benefit compared 
with conventional treatment. Only a few clinically 
important adverse effects were reported during 
PMX haemoperfusion, including cartridge clotting, 
hypotension, and hypersensitivity. Nonetheless, 
the largest multicentre RCT (232 patients) testing 
the performance of PMX haemoperfusion in 
peritonitis-induced septic shock was published in 
April 2015, and reported contrasting findings.26 No 
significant differences in 28-day mortality (27.7% in 
PMX-treated group vs 19.5% in controls; P=0.14), 
haemodynamic patterns, or organ failure evolution 
were observed. This negative result was similar to a 
large retrospective study (642 patients) by Iwagami 
et al27 who examined the effect of postoperative 
PMX haemoperfusion on peritonitis-induced 
septic shock. Patients treated with one or two PMX 
haemoperfusion sessions showed similar mortality at 
day 28 (17%) to propensity-matched patients without 
PMX treatment (16.3%). EUPHRATES (safety and 
efficacy of PMX haemoperfusion for septic shock 
study), a very large multicentre US-based phase III 
trial in patients with confirmed endotoxaemia, is 
currently underway and results should be available 
after July 2017.28 Based on current evidence, the 
clinical benefit of PMX haemoperfusion in Gram-
negative sepsis is unclear. Moreover, the cost of 
individual haemoperfusion cartridges is very high 
(approximately HK$40 000 per cartridge) and limits 
its clinical use in local settings. Currently, PMX-
immobilised fibre column haemoperfusion is not 
available in Hong Kong.
MATISSE-Fresenius system
The MATISSE-Fresenius system (Fresenius SE, Bad 
Homburg, Germany) binds endotoxins to human 
albumin. The extracorporeal circuit is maintained 
by the Fresenius haemoadsorption machine using 
the MATISSE haemoadsorber that contains human 
serum albumin immobilised on polymethacrylate 
beads. Trends in the improvement of morbidity 
and organ dysfunction were reported in initial 
non-randomised studies,29,30 although a subsequent 
multicentre RCT could not identify any significant 
clinical benefit, which then limited its clinical use.31 
Currently, the MATISSE-Fresenius system is not 
available in Hong Kong.
Alteco Lipopolysaccharide Adsorber
The Alteco LPS Adsorber (Alteco Medical AB, 
Lund, Sweden) captures endotoxins using specially 
designed synthetic peptides. This device was 
launched in 2006. Tailor-made synthetic peptides 
with a high affinity for endotoxins are attached to the 
surface of the polyethylene plates using a covalent 
bonding technique. Clinical experience with this 
device is scarce, and is limited mainly to case reports 
and case series.32-34 In general, these case series 
report a shorter vasopressor infusion duration in 
adsorber-treated patients compared with controls. 
Only one underpowered RCT has been published 
by local investigators.35 The study was terminated 
early and showed no significant clinical benefit 
(disease severity score, vasopressor use, length of 
study, and 28-day mortality) following the addition 
of the Alteco LPS Adsorber to conventional therapy 
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in patients who had intra-abdominal sepsis with 
shock.35 The side-effect profile of this novel device 
was acceptable but a recent ex-vivo experimental 
study showed that the Alteco LPS Adsorber could 
not achieve acceptable LPS clearance in serum, 
heparinised plasma, or whole blood.36 Therefore, 
the potential benefit of the Alteco LPS Adsorber in 
sepsis is not clear. 
Cytokines haemoadsorptive device
Several cytokine-absorbing columns have been tested 
in animal studies, showing excellent adsorption rates 
for inflammatory cytokines such as TNF-α, IL-1β, 
IL-6, and IL-8.37 Human data are limited to case 
reports and case series.38-40 CytoSorb (CytoSorbents 
Corporation; Monmouth Junction [NJ], US) is 
a novel synthetic haemabsorption column that 
targets inflammatory mediators.41 It is currently 
the only European-approved extracorporeal device 
for cytokine haemoadsorption. Case reports show 
good cytokine clearance and haemodynamic 
improvement with this device.41-44 Further studies 
focused on clinically relevant endpoints are highly 
recommended. CytoSorb is not available in Hong 
Kong. 
High-adsorption haemofiltration
The AN69 and polymethylmethacrylate (PMMA) 
membrane haemofilters are the currently 
available options for performing high-adsorption 
haemofiltration in septic patients. Both have a 
high cytokine adsorption capacity but surface 
treatment can further modify their haemoadsorptive 
properties.45-47 
oXiris haemofilter
oXiris (Gambro Hospal, Stockholm, Sweden) is an 
AN69-based membrane haemofilter that is surface-
treated with a polyethyleneimine and grafted with 
heparin (Table 2). The AN69 core membrane has 
superior cytokine-binding capacity compared with 
the traditional polysulphone membrane. Surface 
treatment with polyethyleneimine enhances 
endotoxin capture,48 while heparin coating reduces 
membrane thrombogenicity, and prolongs the filter 
life and improves efficiency. A case-control study by 
Shum et al49 involving Gram-negative septicaemic 
patients (n=6) showed that oXiris continuous 
venovenous haemofiltration (CVVH) was associated 
with a greater reduction in Sequential Organ Failure 
Assessment score compared with conventional 
polysulphone-based CVVH (n=24). Subsequent 
large case series (n=40) suggested that oXiris 
treatment had a positive effect on haemodynamics 
with a reduction in cytokine levels (IL-6).50 
Treatment usually lasts for 72 hours (manufacturer’s 
recommendation) and costs approximately HK$8000 
per haemofilter. As of mid 2015, at least five public 
hospitals in Hong Kong have clinical experience with 
oXiris haemofilters in the treatment of septic shock. 
A large-scale RCT will be necessary to determine the 
potential benefit of this device, however.
Polymethylmethacrylate haemofilter
The PMMA membrane has a higher cytokine 
adsorption capacity than the traditional 
polyacrylonitrile and polysulphone membrane.51 
Membrane binding site saturation is one of the 
main concerns during treatment involving highly 
adsorptive haemofiltration. The PMMA haemofilter 
can maintain its cytokine adsorption capacity 
for at least 24 hours after being changed.52 The 
initial clinical experience of PMMA continuous 
haemodiafiltration in the treatment of sepsis is 
encouraging, with significant haemodynamic 
improvement and potential survival benefit.53,54 A 
local RCT (Australian New Zealand Clinical Trial 
Registry ACTRN12611000652976) that is aimed at 
investigating the clinical benefit of PMMA-based 
CVVH in patients with septic shock and AKI is 
currently underway. Treatment usually lasts for 24 
to 48 hours and costs approximately HK$300 per 
haemofilter. 
TABLE 2.  Characteristics of locally available filters used in high cut-off haemodialysis, highly adsorptive haemofiltration, and plasmapheresis
Company Filter name Material Therapy mode Effective surface 
area (m2)
Cut-off 
(kDa)
Machine Blood flow 
(mL/min)
Treatment 
time (hours)
FMC EMiC 2 Polysulphone CVVHD 1.8 40 Multifiltrate 
AK200US
100-350 72 (maximum)
Gambro/Baxter septeX PAES CVVHD 1.1 45 Prismaflex 80-400 24 (maximum)
Gambro/Baxter oXiris AN69 ST CVVH/CVVHDF 1.0 ~20 Prismaflex 100-250 72 (maximum)
Toray BG2.1U PMMA CVVH/CVVHD/ 
CVVHDF
2.1 ~20 Multifiltrate 
AK200US 5008
150-350 24-48
FMC PlasmaFlux Polysulphone Plasmapheresis 0.6 400-800 Multifiltrate 80-250 2-4
Abbreviations: CVVH = continuous venovenous haemofiltration; CVVHD = continuous venovenous haemodialysis; CVVHDF = continuous venovenous 
haemodiafiltration; FMC = Fresenius Medical Care; PAES = polyarylethersulphone; PMMA = polymethylmethacrylate
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High-volume haemofiltration
In 2002, HVHF was defined as >35 mL/kg/h, based 
on recommendations from the Acute Dialysis 
Quality Initiative Workgroup.55 Nonetheless in 
clinical practice, 35 mL/kg/h is not that high and 
can be achieved with ease, especially in those with 
low body weight. To clarify this issue, Honore et 
al56 defined continuous HVHF as 50 to 70 mL/kg/h, 
and 100 to 120 mL/kg/h for 4 to 8 hours followed 
by conventional CVVH as pulse HVHF. In addition, 
HVHF is regarded as effective blood purification 
therapy because circulating inflammatory mediators 
are mostly water-soluble and range between 5 kDa 
and 60 kDa. They are more effectively removed by 
convective means than by diffusion techniques. 
Moreover, haemofilter membranes have some 
adsorptive properties that allow the removal of 
mediators with a molecular weight higher than the 
membrane cut-off point. It is clear that conventional 
haemofiltration with low ultrafiltration rates is 
ineffective for cytokine removal.2,3 Increasing the 
ultrafiltration flow rate can increase the adsorption 
capacity of the haemofilter because of its effect on 
transmembrane pressure (greater membrane site 
recruitment) and the exposure of more available 
adsorptive surface area.57 Only two RCTs that 
investigated the potential benefit of HVHF over 
conventional CVVH in septic patients were available 
before the publication of the landmark trial (high-
volume versus standard-volume haemofiltration 
for septic shock patients with acute kidney injury 
study) in 2013.57,58 Cole et al57 performed the first 
randomised crossover clinical trial that involved 11 
patients with septic shock and multi-organ failure. 
Patients were assigned to either 8 hours of HVHF 
(6 L/h) or 8 hours of standard CVVH (1 L/h) in a 
random order. The results showed that HVHF was 
associated with a greater reduction in vasopressor 
use. A study by Boussekey et al58 (HVHF 65 mL/kg/h 
vs control 35 mL/kg/h; n=20) yielded similar 
findings and showed no survival benefit of HVHF 
over conventional CVVH. Multiple non-randomised 
studies showed decreased mortality with HVHF for 
septic shock patients but most of the studies were 
relatively small.59-61 Despite the initially encouraging 
results, HVHF has not gained in popularity because 
the use of a large volume of ultrapure replacement 
solution equates to significant increases in treatment 
cost, risk of severe electrolyte disturbance, and 
nursing workload. The landmark IVORIE study was 
published in 2013.62 This multicentre RCT involved 
140 critically ill septic shock patients who were 
randomised to receive either HVHF at 70 mL/kg/h 
or standard CVVH treatment at 35 mL/kg/h. It 
showed neither significant survival benefit nor 
haemodynamic improvement for HVHF compared 
with standard treatment. Subsequently two meta-
analyses (4 studies with approximately 500 patients) 
published in 2014 concluded that neither HVHF nor 
pulse HVHF offered any added clinical benefit when 
compared with standard-volume haemofiltration.63,64 
Therefore, the routine use of HVHF for treatment of 
sepsis is not recommended. 
High cut-off haemodialysis/
haemofiltration
Inflammatory mediators are relatively large (TNF-α: 
17 kDa, IL-6: 26 kDa, and IL-8: 8 kDa), and are 
classified as middle molecules. The conventional 
high-flux haemofilter has a cut-off point at 
approximately 20 kDa and is unlikely to achieve 
good cytokine clearance.2,3 The nominal cut-off 
point for HCO membranes ranges from 60 to 150 
kDa and the clinical cut-off point in blood ranges 
from 40 to 100 kDa.65 This can greatly increase 
the sieving coefficients of various inflammatory 
mediators at the expense of loss of albumin (66 
kDa), antithrombin-III (60 kDa), protein C (62 
kDa), and many other vital proteins. Reducing the 
pore size slightly can limit vital protein loss but also 
decrease cytokine removal. Ex-vivo studies showed 
that HCO haemofiltration displayed the greatest 
consistency in cytokine removal when compared 
with standard haemofiltration.66 The CPFA and 
haemoadsorption appeared to offer a similar level of 
cytokine clearance to the HCO technique. Albumin 
loss was comparable between HCO haemofiltration, 
HCO haemodialysis, and HCO haemodiafiltration.66 
Morgera et al67 published the first study on the use of 
HCO haemofiltration among septic shock patients 
and showed good IL-6 (but not TNF-α) clearance. 
Subsequently, Morgera et al68 conducted an RCT 
that involved 30 septic AKI patients who were 
randomised to HCO or conventional haemofiltration. 
The HCO group showed a significant decline in 
vasopressor use and cytokine level.68 The largest 
RCT was the High Cut-Off Continuous Veno-
venous Hemodialysis (CVVHD) in Patients Treated 
for Acute Renal Failure After Systemic Inflammatory 
Response Syndrome (SIRS)/Septic Shock (HICOSS) 
study.69 The estimated sample size was 120 patients 
but the study was terminated early because of a lack 
of difference between the groups after 81 patients 
had been recruited. There was no difference in 
28-day mortality, vasopressor use, duration of 
mechanical ventilation, length of stay in intensive 
care unit, or albumin level between the groups.69 This 
underpowered RCT (due to premature termination) 
cannot provide a clear answer about the potential 
benefit of HCO haemofiltration/haemodialysis in 
septic patients and a further large-scale prospective 
RCT is recommended. Only the septeX (Gambro 
Hospal, Stockholm, Sweden) and EMiC 2 (Fresenius 
SE, Bad Homburg, Germany) HCO haemofilters are 
available in Hong Kong (Table 2). Treatment usually 
lasts for 24 to 72 hours and costs approximately 
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HK$8000 per HCO haemofilter. 
Plasmapheresis and coupled 
plasma filtration adsorption 
The nominal cut-off point for the plasma filter ranges 
from 400 to 800 kDa and therefore can achieve good 
cytokine removal with significant albumin loss 
(Table 2). Only three RCTs have been published 
to date. Busund et al70 published the largest RCT 
involving 106 adult septic patients randomised to 
receive either two sessions of plasmapheresis or 
standard therapy. Plasmapheresis offered better 
28-day survival compared with the control group 
(67% vs 47%). Studies by Reeves et al71 and Long et 
al72 showed no survival benefit, however. Therefore, 
the debate regarding the benefit of plasmapheresis 
in sepsis continues. One important drawback of 
plasmapheresis is the significant loss of albumin, 
fibrinogen, antithrombin, and immunoglobulin 
that takes a long time to regenerate in the absence 
of post-treatment replacement.73 This problem can 
be resolved with the use of CPFA (Lynda, Bellco, 
Mirandola, Italy). This CPFA therapy comprises 
a plasma filter, a non-selective hydrophobic resin 
cartridge with high affinity for inflammatory 
mediators, and a high-flux haemofilter for 
convective solute removal (Fig).74 Only filtrated 
plasma has direct contact with the sorbents that 
have no biocompatibility problems when compared 
with direct haemoperfusion. Treatment lasts for 
approximately 10 hours and requires cartridge 
changes due to saturation problems. Livigni et al75 
published the only multicentre RCT focused on 
patients with septic shock. Patients were randomised 
to standard treatment with or without CPFA. The 
CPFA therapy was performed daily for 5 days and 
lasted at least 10 hours/day. The estimated sample 
size was 330 patients but the study was terminated 
early on the grounds of futility after 192 patients had 
been recruited. No significant benefits for mortality, 
organ dysfunction, or intensive care unit stay were 
observed. Therefore, based on the available evidence, 
the routine use of CPFA for treatment of septic 
shock is not recommended. The CPFA is currently 
not available in Hong Kong. 
Conclusion
Building on the concept of excessive inflammatory 
mediator release, blood purification techniques 
have emerged as an adjunctive therapy for patients 
with severe sepsis and septic AKI. They are effective 
in clearing endotoxin or inflammatory mediators 
and are well tolerated. Despite initially promising 
results, most blood purification techniques have not 
provided any sustainable mortality benefits. In severe 
sepsis, source control, early appropriate antibiotics, 
and haemodynamic support are the three most 
important treatment components.76 As a supportive 
treatment, blood purification techniques may not 
significantly affect patient mortality. Since the 
outcome for septic patients has improved over time, 
much larger sample sizes will be needed to detect 
the relatively small effects of these new therapies 
on sepsis.77 Large-scale, well-designed, prospective 
RCTs are the way forward. The application of these 
novel techniques should be individualised but 
more specific recommendations must await further 
evidence.
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